tiprankstipranks
CV Sciences Inc (CVSI)
OTHER OTC:CVSI
Want to see CVSI full AI Analyst Report?

CV Sciences (CVSI) Price & Analysis

501 Followers

CVSI Stock Chart & Stats

$0.09
>-$0.01(-7.69%)
At close: 4:00 PM EST
$0.09
>-$0.01(-7.69%)

Bulls Say, Bears Say

Bulls Say
Gross Margin ExpansionSustained gross margin improvement, aided by insourcing and lower product costs, increases the company’s structural ability to absorb top-line weakness and fund operating improvements. Higher gross margins strengthen the path to sustained profitability as SG&A is trimmed and scale returns.
Cost Cuts And Cash-flow ImprovementMeaningful, durable cost reductions and improved cash generation demonstrate management’s ability to shrink the structural cash burn. Narrower adjusted EBITDA losses and early positive operating cash flow support the guided move to operating cash-flow breakeven in H2 2026, reducing financing reliance.
Product Diversification & DistributionExpanding beyond CBD with new SKUs and a strong DTC channel enhances revenue mix control and margins long-term. Combined with acquisitions and insourced manufacturing, this structural diversification improves supply control, time-to-market and the ability to capture retail margin sustainably.
Bears Say
Top-line DeclinePersistent revenue and unit-volume declines weaken scale economics and limit the payoff from margin and cost gains. Continued top-line contraction erodes operating leverage, making the path to lasting profitability contingent on reversing demand trends or gaining share in a contracting category.
Weak Cash And Cash FlowLow absolute cash and negative TTM cash flow create structural liquidity risk, constraining investments in product launches, marketing, or inventory. Reliance on financing or convertible notes increases dilution and reduces flexibility to absorb regulatory or market shocks over the medium term.
Regulatory & Category HeadwindsRegulatory uncertainty over hemp/CBD rules and recent legislation can permanently limit product formulations or channels, raising compliance costs and potentially shrinking addressable markets. In a fragmented, contracting CBD category, regulatory risk materially increases execution uncertainty and slows recovery.

CV Sciences News

CVSI FAQ

What was CV Sciences Inc’s price range in the past 12 months?
CV Sciences Inc lowest stock price was $0.01 and its highest was $0.10 in the past 12 months.
    What is CV Sciences Inc’s market cap?
    CV Sciences Inc’s market cap is $4.08M.
      When is CV Sciences Inc’s upcoming earnings report date?
      CV Sciences Inc’s upcoming earnings report date is Aug 17, 2026 which is in 58 days.
        How were CV Sciences Inc’s earnings last quarter?
        CV Sciences Inc released its earnings results on May 14, 2026. The company reported -$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.003.
          Is CV Sciences Inc overvalued?
          According to Wall Street analysts CV Sciences Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does CV Sciences Inc pay dividends?
            CV Sciences Inc does not currently pay dividends.
            What is CV Sciences Inc’s EPS estimate?
            CV Sciences Inc’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does CV Sciences Inc have?
            CV Sciences Inc has 203,977,520 shares outstanding.
              What happened to CV Sciences Inc’s price movement after its last earnings report?
              CV Sciences Inc reported an EPS of -$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.448%.
                Which hedge fund is a major shareholder of CV Sciences Inc?
                Currently, no hedge funds are holding shares in CVSI
                What is the TipRanks Smart Score and how is it calculated?
                Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                  Company Description

                  CV Sciences Inc

                  CV Sciences, Inc. functions as a life sciences organization primarily operating across North America. Its business activities are organized into two distinct divisions: Consumer Products and Specialty Pharmaceutical. The Consumer Products division focuses on the creation, manufacturing, and commercialization of plant-derived dietary supplements and cannabidiol (CBD) products sourced from hemp. These offerings are marketed under various brand identities including PlusCBD, ProCBD, HappyLane, CV Acute, CV Defense, and PlusCBD Pet. They serve a wide array of health and wellness sectors such as nutraceuticals, personal care, specialty food items, and pet products. The company distributes these goods through its own digital platforms, other online retailers, a network of chosen distributors, and traditional brick-and-mortar stores. In contrast, the Specialty Pharmaceutical division is dedicated to the research, advancement, and eventual market launch of cannabinoids for the treatment of specific medical conditions. A key project in this segment involves the drug candidate CVSI-007, an innovative combination of CBD and nicotine designed to combat smokeless tobacco use and dependence. Established in 2010, the company was initially known as CannaVest Corp. before officially adopting the name CV Sciences, Inc. in January 2016. Its main corporate offices are located in San Diego, California.

                  CV Sciences (CVSI) Earnings & Revenues

                  CVSI Earnings Call

                  Q1 2026
                  0:00 / 0:00
                  Earnings Call Sentiment|Positive
                  The call highlights meaningful operational progress: year-over-year margin expansion, a ~13% reduction in operating expenses, improved adjusted EBITDA (loss narrowed to $0.1M), and a notable shift to positive operating cash flow. Management is actively diversifying into non-cannabinoid health products, launching new SKUs, insourcing manufacturing, and integrating recent acquisitions to realize synergies in H2 2026. However, revenue trends remain a concern (down 11% YoY, unit sales down ~12%), GAAP net loss widened to $0.6M, cash on hand is low (~$0.3M), and regulatory uncertainty persists and could require product changes. On balance, the operational and financial improvements and strategic initiatives provide a constructive trajectory toward profitability and cash flow breakeven, outweighing the top-line and regulatory challenges in the near term.View all CVSI earnings summaries
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  cbdMD
                  Cosmos Holdings
                  IM Cannabis Corp
                  Incannex Healthcare Limited Sponsored ADR

                  Ownership Overview

                  <0.01%100.00%
                  Insiders
                  Mutual Funds
                  <0.01% Other Institutional Investors
                  100.00% Public Companies and
                  Individual Investors

                  Options Prices

                  Currently, No data available
                  ---
                  Popular Stocks